EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische Studie

Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer

Javier Cortés, Kevin Punie, Carlos Barrios, Sara A Hurvitz, Andreas Schneeweiss, Joohyuk Sohn iD, Eriko Tokunaga, Adam Brufsky, Yeon Hee Park, Binghe Xu, Roberto Hegg, Mafalda Oliveira und 7 weitere

New England Journal of Medicine · 13.11.2025 · 393 (19) · 1912-1925

DOI: 10.1056/nejmoa2511734 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 13.11.2025. Verfasst von Javier Cortés und 18 weiteren Autor:innen. Beteiligte Einrichtung: International Breast Cancer Center, Pangaea Oncology, Quiron Group, Barcelona. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Camptothecin. Die Arbeit wurde bisher 119-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Gilead Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCamptothecinTriple Negative Breast NeoplasmsAdultAgedFemaleHumansMiddle AgedB7-H1 AntigenCarboplatinDeoxycytidineGemcitabineKaplan-Meier EstimatePaclitaxelProgression-Free SurvivalImmunoconjugatesNeutropeniaSeverity of Illness IndexLeukopeniaAnemiaDiarrheaBreast Neoplasms, MaleMale

Substanzen

Antibodies, Monoclonal, HumanizedAntineoplastic AgentsB7-H1 AntigenCamptothecinCarboplatinDeoxycytidineGemcitabinePaclitaxelsacituzumab govitecanCD274 protein, human

Autor:innen und Institutionen

  • International Breast Cancer Center, Pangaea Oncology, Quiron Group, Barcelona.
  • IOB Madrid, Institute of Oncology, Hospital Beata María Ana, Madrid.
  • Oncology Department, Hospital Universitario Torrejón, Ribera Salud Group, Madrid.
  • Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid.
  • Medica Scientia Innovation Research, Barcelona.
  • Medica Scientia Innovation Research, Ridgewood, NJ.

ORCID-Profile: Joohyuk Sohn

Förderung

  • Gilead Sciences

Zitieren

APA

Cortés, J., Punie, K., Barrios, C., Hurvitz, S. A., Schneeweiss, A., Sohn, J., Tokunaga, E., Brufsky, A., Park, Y. H., Xu, B., Hegg, R., Oliveira, M., Fabi, A., Vaksman, N., Valdez, T., Zhang, X., Lai, C., Tolaney, S. M., & ASCENT-03 Clinical Trial Investigators (2025). Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer. New England Journal of Medicine, 393(19), 1912-1925. https://doi.org/10.1056/nejmoa2511734

Vancouver

Cortés J, Punie K, Barrios C, Hurvitz SA, Schneeweiss A, Sohn J, et al. Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer. New England Journal of Medicine. 2025;393(19):1912-1925. doi:10.1056/nejmoa2511734

BibTeX
@article{Corts2025,
  author = {Cortés, Javier and Punie, Kevin and Barrios, Carlos and Hurvitz, Sara A and Schneeweiss, Andreas and Sohn, Joohyuk and Tokunaga, Eriko and Brufsky, Adam and Park, Yeon Hee and Xu, Binghe and Hegg, Roberto and Oliveira, Mafalda and Fabi, Alessandra and Vaksman, Natalya and Valdez, Theresa and Zhang, Xinrui and Lai, Catherine and Tolaney, Sara M and ASCENT-03 Clinical Trial Investigators, ASCENT-03 Clinical Trial Investigators},
  title = {Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {393},
  number = {19},
  pages = {1912--1925},
  doi = {10.1056/nejmoa2511734}
}
Kostenlos starten →